Mao Lin, Yin Ruili, Yang Longyan, Zhao Dong
Beijing Key Laboratory of Diabetes Prevention and Research, Center for Endocrine Metabolic and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Front Pharmacol. 2025 May 14;16:1573654. doi: 10.3389/fphar.2025.1573654. eCollection 2025.
Diabetic kidney disease (DKD) is a common microvascular complication and the main cause of death in diabetic patients. Metabolic disorders can accelerate the occurrence and development of DKD through a variety of ways, Recent studies have found that Clusterin (Clu) levels are associated with renal dysfunction and can be used as a biomarker of renal tubular injury, while preclinical studies reveal its renoprotective function. This article reviews the molecular mechanisms of Clu in the interaction between various cells in DKD. In addition, we discuss the latest research progress of Clu in the field of DKD. This review aims to explore Clu as a potential therapeutic target for DKD and provide some guidance for future clinical treatment.
糖尿病肾病（DKD）是一种常见的微血管并发症，也是糖尿病患者死亡的主要原因。代谢紊乱可通过多种途径加速DKD的发生和发展。最近的研究发现，簇集素（Clu）水平与肾功能障碍有关，可作为肾小管损伤的生物标志物，而临床前研究揭示了其肾脏保护功能。本文综述了Clu在DKD中各种细胞间相互作用的分子机制。此外，我们还讨论了Clu在DKD领域的最新研究进展。本综述旨在探索Clu作为DKD潜在治疗靶点的可能性，并为未来的临床治疗提供一些指导。
